The SynergiQc-International program is geared to support public/private research with partners outside the province of Quebec ! DEADLINE: OCTOBER 7th, 2019 Montreal, July 16th, 2019 – CQDM has launched the SynergiQc-International funding program that may cover up to 50% of R&D expenses incurred in Quebec as part of a public/private partnership in the biopharmaceutical field, up…
Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics, to improve a novel intracellular delivery technology Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap…
These highly innovative technologies will address unmet medical needs in cancer and diabetes Philadelphia, June 4th, 2019 – Thanks to a C$3.3M contribution from the MEI, and the participation of several partners, CQDM is proud to announce the funding of five collaborative research projects totaling C$15.5M. Headed by world-class experts in the field of cancer and diabetes,…
Montreal, June 1, 2019 – The Canadian Cancer Society (CCS), a leading breast cancer research funder, and CQDM, a Quebec research consortium whose mission is to fund the development of biopharmaceutical technologies and drugs, are proud to announce that nearly $10 million will be invested to fund three breast cancer research projects over the next…
CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the two laureates of the 2019 Gordon Shore Prize, a mark of excellence for new graduates in life sciences Montreal, May 22, 2019 – CQDM, Diazon Pharmaceuticals, the Oncopole, and Mitacs, are delighted to announce the two laureates of the 2019 Gordon Shore Prize: Rachel…
Unique multi-party collaboration forged to develop new anti-cancer therapies targeting DNA repair regulators Montreal, Canada, May 14, 2019 – The NEOMED Institute (NEOMED), CQDM, the Canadian Cancer Society (CCS), the Goodman Cancer Research Centre (GCRC) and the Lady Davis Institute (LDI) announced today a unique multi-party collaboration to develop new anti-cancer therapies. This collaboration is intended…
Montreal, May 2nd, 2019 – CQDM is pleased to announce that Professor Philippe Gros from McGill University has been awarded $1.5 million as part of the SynergiQC program to pursue the development and validation of new inhibitors of ubiquitin-specific protein protease (USP-15) and its partner TRIM25, that plays a key role in neuroinflammation-based disorders. From this…
Two antigens are targeted in combination with the DPX technology developed by IMV Quebec City, Quebec, March 18, 2019 – IMV Inc. (IMV) (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Canadian bioresearch consortium CQDM has awarded a grant to a collaboration among IMV, Centre de recherche du CHU de Québec-Université…
Created by CQDM, Diazon Pharmaceuticals, the Oncopole, and Mitacs, the Gordon Shore Prize is awarded to new graduates whose masters or doctoral thesis demonstrated their research excellence in the life science field. A 6-month post-diploma internship of $24,000 will be offered to each of the awardees by the participating Quebec-based companies: SpecificiT Pharma Inc., Immune Biosolutions…
Montreal, January 29th, 2019. – CQDM is pleased to announce the appointment of Philippe Walker as a member of CQDM’s Scientific Advisory Board. Philippe already knows CQDM very well since he has contributed very closely to its creation and success. Philippe has over 30 years of experience in pharmaceutical research and development in several therapeutic…